NO821192L - Fremgangsmaate for fremstilling av fenetanolaminer. - Google Patents
Fremgangsmaate for fremstilling av fenetanolaminer.Info
- Publication number
- NO821192L NO821192L NO821192A NO821192A NO821192L NO 821192 L NO821192 L NO 821192L NO 821192 A NO821192 A NO 821192A NO 821192 A NO821192 A NO 821192A NO 821192 L NO821192 L NO 821192L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- ethanol
- solvent
- reacted
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- ADCYRBXQAJXJTD-UHFFFAOYSA-N 1-(4-chlorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(Cl)C=C1 ADCYRBXQAJXJTD-UHFFFAOYSA-N 0.000 description 1
- SAKMPXRILWVZEG-UHFFFAOYSA-N 2-bromo-1-(4-chlorophenyl)propan-1-one Chemical compound CC(Br)C(=O)C1=CC=C(Cl)C=C1 SAKMPXRILWVZEG-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010059150 Cerebrosclerosis Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Artificial Filaments (AREA)
- Lubricants (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8107445A FR2503705A1 (fr) | 1981-04-14 | 1981-04-14 | Derives de phenethanolamine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO821192L true NO821192L (no) | 1982-10-15 |
Family
ID=9257367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO821192A NO821192L (no) | 1981-04-14 | 1982-04-13 | Fremgangsmaate for fremstilling av fenetanolaminer. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4430334A (da) |
| EP (1) | EP0063084B1 (da) |
| JP (1) | JPS57179160A (da) |
| AT (1) | ATE9330T1 (da) |
| AU (1) | AU545216B2 (da) |
| CA (1) | CA1185604A (da) |
| DE (1) | DE3260703D1 (da) |
| DK (1) | DK154979C (da) |
| ES (1) | ES8304548A1 (da) |
| FI (1) | FI821288L (da) |
| FR (1) | FR2503705A1 (da) |
| GR (1) | GR75543B (da) |
| HU (1) | HU186492B (da) |
| IE (1) | IE52877B1 (da) |
| IL (1) | IL65493A (da) |
| MX (1) | MX155561A (da) |
| NO (1) | NO821192L (da) |
| NZ (1) | NZ200275A (da) |
| PT (1) | PT74744B (da) |
| ZA (1) | ZA822489B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) * | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| FR2546166B1 (fr) * | 1983-05-19 | 1985-10-25 | Synthelabo | Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique |
| US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
| US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
| FR2672286B1 (fr) * | 1991-01-31 | 1994-11-18 | Synthelabo | Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique. |
| FR2678269B1 (fr) * | 1991-06-27 | 1995-01-13 | Synthelabo | Derives de 1-(4-chlorophenyl)-2-[4-(2-phenylethyl)piperidin-1-yl]ethanol, leur application et leur preparation en therapeutique. |
| FR2696741B1 (fr) * | 1992-10-12 | 1994-11-25 | Synthelabo | Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique. |
| US20070048577A1 (en) * | 2005-08-30 | 2007-03-01 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy Naval Re | Scalable microbial fuel cell with fluidic and stacking capabilities |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (da) * | 1966-09-27 | 1968-01-22 | ||
| DE1618010A1 (de) * | 1967-06-15 | 1970-11-05 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Aminoketonen |
| IE34545B1 (en) * | 1969-10-01 | 1975-06-11 | Continental Pharma | Amino-alcohols,their salts and process for preparing the same |
| AT354187B (de) * | 1976-11-22 | 1979-12-27 | Hoffmann La Roche | Fungizides mittel |
-
1981
- 1981-04-14 FR FR8107445A patent/FR2503705A1/fr active Granted
-
1982
- 1982-04-08 NZ NZ200275A patent/NZ200275A/en unknown
- 1982-04-09 EP EP82400652A patent/EP0063084B1/fr not_active Expired
- 1982-04-09 AT AT82400652T patent/ATE9330T1/de not_active IP Right Cessation
- 1982-04-09 HU HU821112A patent/HU186492B/hu not_active IP Right Cessation
- 1982-04-09 DE DE8282400652T patent/DE3260703D1/de not_active Expired
- 1982-04-13 CA CA000400829A patent/CA1185604A/en not_active Expired
- 1982-04-13 MX MX192243A patent/MX155561A/es unknown
- 1982-04-13 ES ES511365A patent/ES8304548A1/es not_active Expired
- 1982-04-13 FI FI821288A patent/FI821288L/fi not_active Application Discontinuation
- 1982-04-13 ZA ZA822489A patent/ZA822489B/xx unknown
- 1982-04-13 JP JP57061652A patent/JPS57179160A/ja active Granted
- 1982-04-13 US US06/368,002 patent/US4430334A/en not_active Expired - Fee Related
- 1982-04-13 PT PT74744A patent/PT74744B/pt unknown
- 1982-04-13 NO NO821192A patent/NO821192L/no unknown
- 1982-04-13 GR GR67905A patent/GR75543B/el unknown
- 1982-04-13 DK DK165282A patent/DK154979C/da active
- 1982-04-13 IL IL65493A patent/IL65493A/xx unknown
- 1982-04-13 AU AU82555/82A patent/AU545216B2/en not_active Ceased
- 1982-04-14 IE IE869/82A patent/IE52877B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR75543B (da) | 1984-07-27 |
| ZA822489B (en) | 1983-02-23 |
| DK154979B (da) | 1989-01-16 |
| ES511365A0 (es) | 1983-03-01 |
| ATE9330T1 (de) | 1984-09-15 |
| DK165282A (da) | 1982-10-15 |
| EP0063084B1 (fr) | 1984-09-12 |
| AU545216B2 (en) | 1985-07-04 |
| MX155561A (es) | 1988-03-25 |
| HU186492B (en) | 1985-08-28 |
| IL65493A0 (en) | 1982-07-30 |
| PT74744B (fr) | 1985-01-08 |
| FR2503705A1 (fr) | 1982-10-15 |
| ES8304548A1 (es) | 1983-03-01 |
| CA1185604A (en) | 1985-04-16 |
| DK154979C (da) | 1989-07-10 |
| IL65493A (en) | 1985-03-31 |
| IE820869L (en) | 1982-10-14 |
| FI821288L (fi) | 1982-10-15 |
| PT74744A (fr) | 1982-05-01 |
| FR2503705B1 (da) | 1983-11-04 |
| AU8255582A (en) | 1982-10-21 |
| US4430334A (en) | 1984-02-07 |
| JPS6124388B2 (da) | 1986-06-10 |
| JPS57179160A (en) | 1982-11-04 |
| FI821288A0 (fi) | 1982-04-13 |
| EP0063084A1 (fr) | 1982-10-20 |
| NZ200275A (en) | 1984-07-06 |
| DE3260703D1 (en) | 1984-10-18 |
| IE52877B1 (en) | 1988-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1068037A3 (ru) | Способ получени производных 3-(1-пиперидинилалкил)-4 @ -пиридо/1,2- @ / пиримидин-4-она или их фармацевтически приемлимых кислотно-аддитивных солей | |
| Hall Jr | Steric Effects on the base strengths of cyclic amines1 | |
| NO781333L (no) | Fremgangsmaate til fremstilling av 2-(2,2-diarylalkyl)-1-azabicyklo(2.2.2)ocetan og beslektede forbindelser | |
| NO821192L (no) | Fremgangsmaate for fremstilling av fenetanolaminer. | |
| DE68924751T2 (de) | Azacyclische Verbindungen, verwendbar als Arzneimittel. | |
| NO315852B1 (no) | Piperazinoderivater som neurokininantagonister, farmasöytiske preparater som omfatter slike forbindelser, og anvendelse av forbindelsene tilfremstilling av medikamenter | |
| NO150916B (no) | Analogifremgangsmaate ved fremstilling av et terapeutisk aktivt fenoksypropanolaminderivat | |
| CH637653A5 (de) | In 11-stellung substituierte 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| NO141161B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive morfinanderivater | |
| HUT53867A (en) | Process for producing new pyrrolidine derivatives and pharmaceutical compositions comprising such compounds | |
| CA1072960A (en) | Indolo (3,2,1-de) (1,5) naphthyridine derivatives | |
| IE912261A1 (en) | New oxazolopyridine compounds, process for preparing these¹and pharmaceutical compositons containing them | |
| NO127447B (da) | ||
| PT86394B (pt) | Processo para a preparacao de novas diazepinonas condensadas e de composicoes farmaceuticas que as contem | |
| US3579512A (en) | 1-(4-piperidyl)-butanones | |
| NO162017B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive alfa-aryl-alfa-pyridylalkansyrederivater. | |
| AU2001292236B2 (en) | 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis | |
| NO770655L (no) | Fremgangsm}te til fremstilling av e iminoforbindelser. | |
| Diamond et al. | Synthesis and properties of the analgesic DL-α-1, 3-dimethyl-4-phenyl-4-propionoxyazacycloheptane (Proheptazine) | |
| NO141753B (no) | Analogifremgangsmaate for fremstilling av nye propanolaminer med beta-reseptor blokkerende og alfa-reseptor blokkerende effekt | |
| NO137893B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive 1-m-trifluormetylfenyl-2-cyanoalkylaminopropaner | |
| CA1136632A (en) | 2-amino-3(4 or 5)-pyridinyl)-phenols, preparation and cardiotonic use | |
| JPS5810387B2 (ja) | ４，５，６，７テトラヒドロイミダゾ〔４，５−ｃ〕ピリジン誘導体及びその製法 | |
| DE2313625C2 (de) | &alpha;-(Aminoalkyl)-4-hydroxy-3-(methylsulfonylmethyl)-benzylalkohole, ihre Salze, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| PL142604B1 (en) | Method of obtaining novel derivatives of azabicyclo/3.3.1/nonane |